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ABSTRACT: Silk nanoparticles are viewed as promising vectors
for intracellular drug delivery as they can be taken up into cells by
endocytosis and traﬃcked to lysosomes, where lysosomal enzymes
and the low pH trigger payload release. However, the subsequent
degradation of the silk nanoparticles themselves still requires study.
Here, we report the responsiveness of native and PEGylated silk
nanoparticles to degradation following exposure to proteolytic
enzymes (protease XIV and α-chymotrypsin) and papain, a cysteine
protease. Both native and PEGylated silk nanoparticles showed
similar degradation behavior over a 20 day exposure period
(degradation rate: protease XIV > papain ≫ α-chymotrypsin).
Within 1 day, the silk nanoparticles were rapidly degraded by
protease XIV, resulting in a ∼50% mass loss, an increase in particle
size, and a reduction in the amorphous content of the silk secondary
structure. By contrast, 10 days of papain treatment was necessary to observe any signiﬁcant change in nanoparticle properties,
and α-chymotrypsin treatment had no eﬀect on silk nanoparticle characteristics over the 20-day study period. Silk nanoparticles
were also exposed ex vivo to mammalian lysosomal enzyme preparations to mimic the complex lysosomal microenvironment.
Preliminary results indicated a 45% reduction in the silk nanoparticle size over a 5-day exposure. Overall, the results demonstrate
that silk nanoparticles undergo enzymatic degradation, but the extent and kinetics are enzyme-speciﬁc.
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■ INTRODUCTION
The biopolymer silk has a long clinical track record, as silk from
domesticated silkworms (Bombyx mori) has been used in
medical applications for many centuries.1 Even today, silk
remains the preferred material for specialized suture
applications (e.g., eye surgery)1 due to its exquisite handling
and toughness.2,3 Recently, silk has been approved for human
use in surgical meshes (Allergan Inc., U.S.A.) designed for soft
tissue repair and reconstruction.4 However, silk is also a
promising biopolymer for emerging biomedical applications,
because of (i) the extensive clinical experience with silk, (ii) the
all-aqueous silk processing technology, (iii) the ability of silk to
stabilize and protect therapeutic payloads, and (iv) the capacity
to reverse engineer silk into ﬁlms, scaﬀolds, hydrogels, and
micro- and nanoparticles (reviewed in refs 5−7). Silk
nanoparticles can be surface decorated with polyethylene glycol
(PEG) to improve colloidal stability in physiological ﬂuids and
to allow evasion of immune recognition.8,9
Native and PEGylated silk nanoparticles (size approximately
100 nm) are often proposed for solid tumor drug targeting
(reviewed in ref 5). Following intravenous dosing, these
nanoparticles circulate in the blood, extravasate at the tumor
site due to leaky blood vessels, and accumulate due to impaired
lymphatic drainage. This phenomenon is commonly referred to
as the “enhanced permeation and retention” (EPR) eﬀect,10,11
but full clinical exploitation of the EPR eﬀect remains to be
realized.12,13 The payloads of nanoparticles can diﬀer widely,
but the nanoparticles must reach the tumor microenvironment
and must often deliver the payload to a speciﬁc intracellular
destination to elicit the desired pharmacological eﬀect. For
example, native and PEGylated silk nanoparticles are typically
designed for lysosomotropic drug delivery;8,14 therefore, they
need to traﬃc into lysosomes, where the low pH and lysosomal
enzymes trigger payload release.15 However, the subsequent
fate and the material properties of the native and PEGylated
silk nanoparticles that accumulate within lysosomes is
unknown.
The silk protein is considered biodegradable because it is
sensitive to proteolytic enzymes (e.g., protease K, protease XIV,
collagenase, and α-chymotrypsin) and enzyme-catalyzed
hydrolysis reactions.16 The hydrophilic amorphous segments
within the silk heavy chain, as well as the C- and N-terminal
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sequences (which consist of completely nonrepeating amino
acid residues), are particularly susceptible to proteolytic
degradation. The degradation of monolithic silk ﬁlms17 and
porous silk scaﬀolds18 has been studied extensively both in vitro
and in vivo. However, the degradation behavior is inﬂuenced by
a number of factors, including (i) silk secondary structures (e.g.,
beta-sheet content), (ii) silk format (e.g., monolithic ﬁlm versus
porous scaﬀold), (iii) exposure time, and (iv) enzyme types
(these vary among cells as well as subcellular locations).17−20
The degradation products of silk-based biomaterials are
expected to be noncytotoxic.21 However, the enzymatic
degradation behavior of silk nanoparticles is poorly deﬁned,
especially for silk nanoparticles intended for lysosomotropic
drug delivery. Our goal was therefore to investigate the
degradation of native and PEGylated silk nanoparticles by
monitoring the secondary structure, zeta potential, particle size,
mass loss, and morphology following exposure to protease
enzymes (protease XIV and α-chymotrypsin) and a cysteine
protease, papain, which resembles the mammalian lysosomal
enzymes, cathepsins B, H, L, and S.22 The morphology and
particle size distribution of native and PEGylated silk
nanoparticles were also examined following ex vivo exposure
to enzymes from lysosomes isolated by subcellular fractionation
of rat liver.
■ EXPERIMENTAL METHODS
Preparation of Reverse Engineered Silk Solution. Silk was
extracted from Bombyx mori silk cocoons using a 60 min degumming
time and was fully reverse engineered to yield an aqueous silk solution,
as described previously.8
Preparation of Native and PEGylated Silk Nanoparticles. Silk
nanoparticles were generated using nanoprecipitation; a video format
for the preparation of native silk nanoparticles has been reported
previously.23 When indicated, the silk nanoparticles were surface
modiﬁed with TST-activated mPEG 5000, as reported.8 The native
and PEGylated silk nanoparticles were stored at 4 °C until use.
Isolation of Lysosomes from Rat Liver. Diﬀerential and
gradient centrifugation was used to isolate rat liver lysosomes. The
lysosomal preparation was characterized and subjected to quality
control measures (detailed in the Supplementary Methods).
Degradation of Native and PEGylated Silk Nanoparticles by
Protease Enzymes and a Lysosomal-Like Enzyme. Protease XIV
from Streptomyces griseus (3.5 units per mg enzyme), α-chymotrypsin
from bovine pancreas (40 units per mg enzyme), and papain
(lysosomal-like enzyme) from Carica papaya latex (10 units per mg
enzyme) were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.).
The enzymatic activities were ﬁxed at 3.5 enzyme units (U) for all
subsequent degradation studies. Therefore, 1 mg/mL protease XIV,
0.0875 mg/mL α-chymotrypsin, and 0.35 mg/mL papain were freshly
prepared by dissolving the respective enzyme powder in ultrapure
water. The 10 mg/mL native and PEGylated silk nanoparticles were
exposed to these enzymes, and the enzymes were recharged (i.e.,
keeping enzyme activity at 3.5 U) every 5 days for up to 20 days. All
samples were incubated at 37 °C and analyzed at 1, 3, 5, 10, and 20
days.
Ex Vivo Degradation of Native and PEGylated Silk Nano-
particles Exposed to Lysosomal Enzymes. A 0.5 mL lysosome-
rich fraction was added to a 0.1 mL Slide-A-Lyzer Mini Dialysis Device
(MWCO 3500 g mol−1; Thermo Scientiﬁc, Waltham, MA, U.S.A.)
and was dialyzed against 1 L ultrapure water at 4 °C for 24 h to
remove the buﬀer. The functional capacity of this buﬀer-free
lysosomal-rich fraction was veriﬁed with the N-acetylglucosaminidase
(NAG) assay. Native and PEGylated silk nanoparticles were treated
with 3.5 U/mL lysosomal enzymes (enzyme activity 0.105 U/mL): 30
μL of 3.33 mg/mL native and PEGylated silk nanoparticles containing
0.1 mg nanoparticles were treated with 333 μL of lysosomal enzymes
in 400 μL of acidiﬁed water, pH 5.5, containing 5 mM glutathione and
2 mM EDTA. The samples were incubated at 37 °C with the enzymes
for 5 days. Silk nanoparticle morphology and particle size distribution
were then studied by scanning electron microscopy. Zeta potential
measurements were performed as detailed below.
Nanoparticle Mass Loss. Native and PEGylated silk nanoparticles
were exposed to model enzymes and incubated at 37 °C in 2 mL
Eppendorf tubes. The controls were (i) native silk particles in water,
(ii) PEGylated silk nanoparticles in water, and (iii) respective model
enzymes in water; the control samples were treated identically to the
respective enzyme-treated samples. All Eppendorf tubes were weighed
before adding the sample (W1). On treatment days 1, 3, 5, 10, and 20,
the samples were centrifuged at 16 000g for 40 min. The pellet and
supernatant were collected, frozen, and lyophilized. The tubes
containing freeze-dried pellets were weighed (W2) to determine the
nanoparticle mass remaining after the treatment using (eq 1) (silk
nanoparticles in water served as the control; i.e., 100% weight).
= − ×% mass remaining (W2 W1)
weight of control nanoparticles
100
(1)
Particle Size and Zeta Potential. The changes in particle size
and zeta potential were determined by dynamic light scattering (DLS,
Zetasizer Nano-ZS Malvern Instrument, Worcestershire, U.K.) for
native and PEGylated silk nanoparticles treated with and without
enzymes for 1, 3, 5, 10, and 20 days. Refractive index values of 1.33 for
ultrapure water and 1.60 for silk were used for computation of particle
size.
Secondary Structure Measurement. Untreated and enzyme-
treated silk nanoparticles were centrifuged, washed with ultrapure
water, frozen, and then freeze-dried. The samples were subjected to
Raman and Fourier transform infrared (FTIR) spectroscopy to
determine the secondary structure of silk. Raman spectra measure-
ments were performed using a Raman XploraA microscope (Horiba
Jobin Yvon, Villeneuve d’Ascq, France). The 50× objective lens was
used, and the laser wavelength was 532 nm. The spectrum was
recorded between 50 and 3500 cm−1, with 2 accumulations for 20 s
per acquisition using a grating with 1200 grooves mm−1. FTIR was
carried out using a TENSOR II FTIR spectrometer (Bruker Optik
GmbH, Ettlingen, Germany). Each measurement was run for 128
scans at 4 cm−1 resolution over the wavenumber range of 400 to 4000
cm−1. OriginPro 9.2 software was used to correct baselines and peak
ﬁts at the amide I region (1595−1705 cm−1). Brieﬂy, the amide I
region was identiﬁed and deconvoluted:24 1605−1615 cm−1 as side
chain/aggregated strands, 1616−1637 cm−1 and 1697−1703 cm−1 as
β-sheet structure, 1638−1655 cm−1 as random coil structure, 1656−
1662 cm−1 as α-helical bands, and 1663−1696 cm−1 as β-turns. The
second derivative was applied at the amide I region for peak ﬁnding.
Gaussian line shapes were used for curve ﬁtting. Overﬁtting of the data
was avoided by ﬁxing the peak full width at half-maximum at 10 cm−1.
Scanning Electron Microscopy. The morphology of native and
PEGylated silk nanoparticles before and after enzyme treatment was
imaged by scanning electron microscopy (SEM) using a FE-SEM
SU6600 instrument (Hitachi High Technologies, Krefeld, Germany)
at 5 kV. Samples were pipetted onto a silicon wafer and lyophilized
overnight. The specimens treated with model enzyme were coated
with carbon using a vacuum coater (Polaron Division E6100, Bio-Rad,
Birmingham, UK), while the specimens of ex vivo lysosomal-treated
nanoparticles were sputter-coated with 15 nm of gold using an
ACE200 low vacuum sputter coater (Leica Microsystems, Wetzlar,
Germany). The subsequent SEM images were analyzed using ImageJ
v1.50i software (National Institutes of Health, Bethesda, MD, U.S.A.).
Statistical Analyses. Data were analyzed using GraphPad Prism
7.0 (GraphPad Software, La Jolla, CA, U.S.A.). Multiple samples were
evaluated by one-way analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison post hoc test. An asterisk denotes
statistical signiﬁcance as follows: *P < 0.05, **P < 0.01, ***P < 0.001.
All data are presented as mean values ± standard deviation (SD), and
the number of independent experiments (n) is noted in each ﬁgure
legend.
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■ RESULTS
Nanoparticle Mass Loss in Response to Enzymes. The
mass of native and PEGylated silk nanoparticles exposed to
protease XIV dropped rapidly to 40% and 60%, respectively, of
the original mass within 1 day. The degradation rate
subsequently slowed after the 3-day treatment cycle. The
mass loss of native and PEGylated silk nanoparticles treated
with papain gradually decreased from day 1 to day 5, resulting
in a loss of more than 50% after 10 days of treatment. By
contrast, no signiﬁcant change was noted in the mass of the
native or PEGylated silk nanoparticles after α-chymotrypsin
treatment (Figure 1).
Impact of Enzymes on Particle Size and Zeta Potential
Changes. The particle size and zeta potential of control native
silk nanoparticles were 94.44 nm ± 3.03 and −45.2 mV ± 1.6,
respectively, whereas the particle size and zeta potential of the
control PEGylated silk nanoparticles were 108.5 nm ± 3.72 and
−37.3 mV ± 1.4, respectively. The particle size increased over
the 20-day treatment cycle for the native and PEGylated silk
nanoparticles treated with protease XIV (Figure 2). The
negative zeta potentials for silk nanoparticles were shifted
toward a less negative value over the treatment period (Figure
2). The size of the silk nanoparticles exposed to papain
signiﬁcantly increased and had reached 2.2 and 1.5 μm for
native and PEGylated silk nanoparticles, respectively, by day 10
(Figure 2). The zeta potential of silk nanoparticles treated with
papain was considerably shifted toward a more neutral value
after the 10-day treatment cycle. By contrast, no change was
noted in the size or surface charge of the nanoparticles exposed
to chymotrypsin (Figure 2A,C).
Eﬀect of Proteolytic Enzymes on the Secondary
Structure of Silk. The secondary structure of native and
PEGylated silk nanoparticles before and after enzyme exposure
was analyzed by FTIR and Raman spectroscopy (Figure 3 and
Figure 4). The Raman bands at 1665 and 1229 cm−1 represent
β-sheet structure in the amide I and amide III regions,
respectively. The two bands at 1104 and 1084 cm−1 are due to
alanine in coils/helix and β-sheet conformations, respectively.25
The Raman spectra showed similar results for both native and
PEGylated silk nanoparticles treated with model enzymes. The
amide I (1665 cm−1) and amide III (1229 cm−1) region of the
nanoparticles did not change following enzyme treatment.
Figure 1. Nanoparticle mass loss after enzyme treatment of native and PEGylated silk nanoparticles. (A) The native silk nanoparticles and (B)
PEGylated silk nanoparticles were treated with the respective enzymes and the remaining mass of nanoparticles over 20 days was measured. Data are
from three independent experiments (n = 3) ± SD; error bars are hidden within the plot symbols when not visible.
Figure 2. Particle size and zeta potential measurement of native and PEGylated silk nanoparticles following exposure to enzymes. Shifts in particle
size and zeta potential of enzyme-treated (A) native silk and (B) PEGylated silk nanoparticles over the 20-day treatment cycle at 37 °C. Data from
three independent experiments (n = 3) ± standard error of the mean; error bars are hidden in the bars when not visible.
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However, silk nanoparticles treated with protease XIV and
papain showed peak broadening at 1104 and 1084 cm−1 over
the 20-day treatment cycle (Figure 3).
For FTIR analysis, the amide I bands at 1621 and 1640 cm−1
are attributed to β-sheet and amorphous structures, respec-
tively.24 The amide I region of the native and PEGylated silk
nanoparticles did not change over the 20-day enzyme treatment
cycle, when compared with the control (Figure 4).
Fourier self-deconvolution (FSD) was applied to extract the
secondary structure content (%) from the FTIR spectra of the
enzyme-exposed silk nanoparticles (Figure 4). The percentage
contribution to the secondary conformation of the structural
elements was derived from the area under the individual
deconvoluted peaks (Figure S1). The observed changes were
similar for both native and PEGylated silk nanoparticles.
However, marked diﬀerences were evident, depending on the
enzymes tested. Protease XIV reduced random coil/α-helix
structure and β-turns, which resulted in a proportional increase
in β-sheet structure of the silk nanoparticles (Figure 5). The
increase in β-sheets was attributed to the increase in
intermolecular β-sheet content over the 20-day treatment
cycle (Figure S2). Papain decreased the overall β-sheet content
Figure 3. Raman spectra of native and PEGylated silk nanoparticles after enzyme degradation. The lines in the Raman spectra at 1665, 1229 and
1084 cm−1 represent β-sheets, whereas 1104 cm−1 represents the amorphous segments.
Figure 4. Determination of FTIR absorbance spectra of the amide I region of enzyme-treated native and PEGylated silk nanoparticles over time. The
lines mark the absorbance band at 1621 and 1640 cm−1, representing antiparallel β-sheets and random coils/helixes, respectively.
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after 10 days of enzyme treatment due to a reduction in the
content of intermolecular β-sheets within the silk nanoparticles
(Figure S2). Consequently, a proportional increase was
observed in the random coil/α-helix structure. Alpha-
chymotrypsin treatment decreased the random coil and α-
helix content of silk nanoparticles at day 1, but the content was
restored to control values by day 3 and was maintained until
day 20 (Figure 5). By contrast, α-chymotrypsin did not aﬀect
the secondary structure of PEGylated silk nanoparticles over
the 20-day treatment cycle (Figure 5).
Figure 5. Quantiﬁcation of the secondary structure (%) of enzyme-treated native and PEGylated silk nanoparticles over time. Secondary structures:
β-sheets, random coil, and α-helix, side chain/aggregated stands and β-turns of (A) silk nanoparticles and (B) PEGylated silk nanoparticles over the
20-day enzyme treatment cycle.
Figure 6. Scanning electron microscopy (SEM) images of native and PEGylated silk nanoparticles after 20 days of treatment with or without
enzymes (scale bar = 1 μm).
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Morphology Changes of Nanoparticles. Electron
microscopy studies indicated that native and PEGylated silk
nanoparticles were spherical particles in the nanometer size
range (100 to 120 nm) (Figure 6). The morphological changes
were similar for both native and PEGylated silk nanoparticles
following enzyme treatment. Nanoparticles exposed to protease
XIV for 1 day aggregated and appeared swollen, porous, and
irregularly shaped. The continuous degradation of silk by
protease XIV was accompanied by a change to a more compact
morphology. Nanoparticles treated with papain remained
within the nanometer size range and retained a spherical
shape after 1 day of treatment; however, the particles were
signiﬁcantly degraded and were closely packed into micrometer
sized particles without pores after the 20-day enzyme exposure.
By contrast, nanoparticles exposed to α-chymotrypsin did not
change in shape or size over the 20-day treatment cycle (Figure
6).
Characterization of the Nanoparticles Exposed to
Isolated Lysosomal Enzymes. The morphological changes
of native and PEGylated silk nanoparticles were investigated by
SEM following a 5-day ex vivo lysosomal enzyme treatment.
The particle size of enzyme-degraded silk nanoparticles was
heterogeneous and averaged 75.7 ± 27.9 nm (Figure 7A). The
silk nanoparticles aggregated after enzyme exposure and
showed irregular shapes; evidence of residual material was
visible on the mica surface (Figure 7A open arrow). The zeta
potential of native silk nanoparticles exposed to lysosomal
enzymes dropped substantially to a near-neutral value after 1
day of treatment (Figure 7A). By contrast, the particle size
distribution remained more homogeneous (64.9 ± 14.7 nm)
with only small changes to the zeta potential for the enzyme-
treated PEGylated silk nanoparticles, which showed no/little
aggregation and less residual material overall on the surface
(Figure 7B).
■ DISCUSSION
Nanoparticles designed for lysosomotropic drug delivery need
to successfully navigate from the injection site to their ﬁnal
destination (i.e., the lysosomes) to elicit the desired therapeutic
response.5 Silk nanoparticles are readily traﬃcked in vitro to
lysosomes, where the acidic environment and proteolytic
enzymes trigger drug release.15 However, the impact of the
lysosomal environment on the fate and material properties of
native and PEGylated silk nanoparticles is unknown. The
accumulation of PEGylated nanoparticles in lysosomes imposes
a potential risk of evoking a “lysosomal storage disease-like”
response, when the material destined for lysosomal degradation
is not degraded at a suﬃcient rate but instead accrues and
perturbs organelle function.26,27
Clinical experience with nonbiodegradable polymers, such as
N-(2-hydroxypropyl)methacrylamide (HPMA)28 and poly-
ethylene glycol (PEG),29 has been encouraging. Nonetheless,
Figure 7. Qualitative and quantitative analysis of native and PEGylated silk nanoparticles following lysosomal enzyme exposure. Scanning electron
microscopy (SEM) images, particle size distribution, and zeta potential of (A) native silk nanoparticles and (B) PEGylated silk nanoparticles after a
5-day exposure to ex vivo lysosomal enzymes (scale bar = 1 μm). For SEM images closed arrows denote the remaining nanoparticles and open
arrows denote degradation products. The normal distributions show the particle size distribution of nanoparticles (dashed line) and enzyme-treated
nanoparticles (solid line).
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the safety window for HPMA- and PEG-based nanomedicines
depends on a multitude of factors, including (but not limited
to) dosing frequency (i.e., chronic versus acute), polymer dose,
and polymer characteristics (e.g., architecture, end group
functionality, molecular weight, polydispersity, etc.). Non-
clinical toxicology studies with clinically approved PEGylated
Figure 8. B. mori schematic and cleavage sites of proteolytic enzymes of the silk amino acid sequence. (A) Two dimensional schematic of silk
structure including the heavy chain (i.e., N-terminus, crystalline β-sheets, amorphous, and C-terminus) and light chain. (B) Enzymatic speciﬁcities of
proteolytic enzymes for the silk sequences. The silk amino acid sequences was extracted from Prot/TrEMBL accession numbers P05790 and
P21828. (C) Number of cleavage sites of proteolytic enzymes on diﬀerent silk domains.
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biopharmaceuticals have shown evidence of (transient)
vacuolation, primarily in phagocytic cells.30 Furthermore,
metabolic reprogramming of macrophages with (silk) nano-
particles has recently been reported.31
Silk has a remarkable clinical track record, and it is degraded
by proteolytic enzymes,32 but the response to enzymes when
silk is in nanoparticle form is unknown. Simply assuming that
silk nanoparticles will behave similarly to other macro-sized silk
formats is not scientiﬁcally rigorous.5 Furthermore, material
performance is context speciﬁc and thus requires dedicated
assessments. The present study represents the ﬁrst inroads into
the assessment of silk nanoparticle degradation by proteolytic
enzymes.
The proteolytic susceptibility of both native and PEGylated
silk nanoparticles was determined by assessing the mass loss in
response to enzyme exposure. All the silk nanoparticle
responses showed a similar rank order (protease XIV > papain
≫ α-chymotrypsin) (Figure 1). Previous studies with silk ﬁlms
and hydrogels also demonstrated that silk degradation was
signiﬁcantly faster with protease XIV than with α-chymo-
trypsin.19 The silk sequence alignment indicates 434 α-
chymotrypsin cleavage sites in the silk heavy chain and 81 in
the light chain, and 348 and 41 Protease XIV cleavage sites in
the heavy and light chains, respectively19 (Figure 8, Figure S5).
Thus, the diﬀerences in silk degradation are not governed only
by the number of cleavage sites but are critically dependent on
enzyme accessibility, the silk format, and the secondary
structure of the silk.
In the current study, degradation was slower at the early time
points (i.e., day 1 enzyme exposure and the resulting mass loss
and particle size) for PEGylated silk nanoparticles than for
native silk nanoparticles for all the tested enzymes (Figure 1
and 2). This relatively lower degradation rate for PEGylated silk
probably reﬂects the ability of PEG to shield the silk surface and
thus hinder the access of the proteolytic enzymes. This
protective eﬀect concurs with indirect observations in single
breast cancer cells,15 where a slower therapeutic payload release
was observed from PEGylated silk nanoparticles than from
native silk nanoparticles, suggesting a reduced proteolytic
degradation.
We also measured the particle size and charge in response to
enzyme treatment. We observed signiﬁcant swelling of silk
nanoparticles, as reported for other protein-based nanoparticles
(e.g., human serum albumin).33,34 We therefore speculate that
proteolytic enzymes disturbed the silk packing geometry
permitting greater water ingress that resulted in particle
swelling. Simultaneously, degradation reduced surface charges
(Figure 2) enabling degradation products to loosely accumulate
on the remaining particle surface (Figure 6). Increases in
particle size were readily observed from day 10 onward, and
these changes were particularly evident for the papain-treated
silk nanoparticles (Figure 2). Papain exposure progressively
changed the negative zeta potential of silk nanoparticles toward
more positive values. This was particularly evident for the
native silk nanoparticles and less so for the PEGylated ones,
which suggested that PEGylation could provide steric
hindrance and protection against proteolytic degradation
(Figure S6). Silk sequence alignment showed that 26 sites in
the silk heavy chain and 15 sites in the light chain are
susceptible to cleavage by papain (Figure 8 and Figure S5).
Papain cleaves arginines and lysines of the silk sequence; the
latter one is also exploited for PEGylation in addition to
histidine and tyrosine.5 Papain cleavage of lysines and arginines
would be expected to lead to a net loss of positive charge. Thus,
the observed overall loss of the negative zeta potential is
counterintuitive and requires more work to explain the
experimental data. Similar considerations apply for protease
XIV (Figure 2). By contrast, α-chymotrypsin treatment did not
change the particle size or zeta potential of either the native or
the PEGylated silk nanoparticles over the 20 day treatment
cycle, as reﬂected by the maintenance of a consistent
nanoparticle mass (Figure 1). Previous studies using silk ﬁlms
and hydrogels also reported minimal degradation by α-
chymotrypsin.19
We used Raman and FTIR spectroscopy to obtain a better
understanding of the changes in native and PEGylated silk
nanoparticles following enzyme treatment. The amide I band in
FTIR and the amide I and III bands in Raman are well-suited
for assigning secondary structures to proteins,35 and they are
also widely applied to silk.36 The typical wavenumbers in
Raman spectroscopy for protein secondary structure are 1662−
1655, 1272−1264, and 1104 cm−1 for random coils/α-helixes
and 1674−1672, 1242−1227, and 1084 cm−1 for β-sheets.25,37
The Raman spectra of native and PEGylated silk nanoparticles
showed signal intensities at 1665, 1229, and 1084 cm−1, which
indicated a β-sheet conformation for silk (Figure 3). No
changes were evident in the amide I spectra of the enzyme-
treated nanoparticles due to the lower sensitivity of the Raman
versus the FTIR spectra.38 However, the band at 1104 and
1084 cm−1 was used to analyze secondary structure changes of
silk nanoparticles. The bandwidth in this region became
progressively broader for silk nanoparticles exposed to protease
XIV and papain, from 5 days onward, indicating that these
enzymes digested β-sheet sequences.
The FTIR measurements conﬁrmed that both native and
PEGylated silk nanoparticles had high β-sheet contents (i.e.,
high amide I absorbance at 1621 cm−1). The overall silk FTIR
spectra bands did not show visible changes following enzyme
exposure (Figure 4), so Fourier self-deconvolution (FSD) was
applied to quantify the secondary structure.24 Protease XIV
emerged as the most powerful proteolytic enzyme, as it caused
substantial changes in the secondary structure of both native
and PEGylated silk nanoparticles. Protease XIV can cleave
many amino acids (e.g., histidine, phenylalanine, tryptophan,
tyrosine, lysine, and arginine) that are found in the crystalline
(222 sites) and amorphous regions (84 sites) (Figure 8).
Overall, protease XIV has a low speciﬁcity, which facilitates its
degradation of the crystalline and amorphous regions of silk.19
Conceivably, protease XIV ﬁrst degraded the surface residues,
which are expected to be present as random coils/α-helixes,
followed by β-sheets, which are found in the core of the silk
nanoparticle.
We also included papain in our study because it is a cysteine
protease enzyme that mimics the activity of lysosomal
enzymes.22,39 It can hydrolyze peptide bonds formed by the
carboxyl groups of lysine and arginine and adjacent amino acid
residues.22,39 These lysine and arginine amino acid residues are
found both in the heavy and light silk chain. However, they are
not found in the crystalline domains, but four sites are present
in the amorphous segments of the silk heavy chain and 22 sites
in the C- and N-termini, as well as 15 sites in the silk light chain
(Figure 8). By contrast, secondary structure analysis of silk
nanoparticles treated with α-chymotrypsin showed no evidence
of silk structural changes in either the crystalline or the random
coil/α-helix structures. These observations were supported by
morphological studies and the absence of loss of mass over the
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20-day treatment cycle. The resistance of silk to α-
chymotrypsin digestion over short time frames has also been
reported by others.19
We next examined the morphological changes following
enzymatic degradation of native and PEGylated silk nano-
particles (Figure 6). Protease XIV eﬀectively digested both
native and PEGylated silk nanoparticles and elicited gross
changes in morphology within 24 h. A slower, but similar,
degradation pattern was observed following the papain
treatment. The morphologies observed in the present study
diﬀered from those previously reported for silk ﬁlms treated
with protease XIV.40,41 Our experience with silk ﬁlms suggests
that the silk format (i.e., nanoparticle versus ﬁlm) as well as the
processing parameters (e.g., water annealing, slow drying, and
stretching) aﬀects the degradation.40 The generation of
nanoﬁlaments (up to 10 nm thick and with a 10 μm surface
area)41 has been reported following protease XIV treatment of
silk crystals, but no nanoﬁlaments were observed in the present
study. We also did not observe any noticeable silk degradation
in response to α-chymotrypsin treatment. The SEM images
conﬁrmed that α-chymotrypsin treatment had no detectable
eﬀect on the silk nanoparticle morphology (Figure 6).
Protease XIV is a useful model enzyme for studying the
fundamental principles of silk degradation (and for direct
comparison with many previous reports that typically use
protease XIV). In the current study, we also included α-
chymotrypsin because it is a relevant mammalian enzyme
(unlike protease XIV which is a nonmammalian enzyme) (see7
for discussion). However, silk nanoparticles are typically
designed for lysosomotropic drug delivery; thus, the degrada-
tion behavior of silk nanoparticles in response to lysosomal
enzymes is most relevant. We used the lysosomal model
enzyme papain (discussed above and used at equivalent
enzymatic units to permit direct comparisons), as well as
lysosomes isolated from mammalian tissue. First, we isolated
and extensively characterized our lysosomal preparation (see
Supporting Information). The preliminary results from ex vivo
lysosomal degradation studies showed that native and
PEGylated silk nanoparticles were slowly degraded over the
initial 5 days, as evidenced by a reduction in particle size,
changes in surface charge as well as by the formation of visible
degradation products (Figure 7). As expected, PEGylation was
able to slow silk nanoparticle degradation and conserve surface
charge; in contrast, native silk nanoparticles showed a reduction
in surface charge already at day 1. This was expected because
model enzymes showed a similar trend (Figure 2). We note
that high vacuum SEM images did not show obvious signs of
particle swelling and we speculate that sample preparation for
SEM imaging might be responsible for this. Technical
limitations (e.g., the diﬃculty of keeping a constant 3.5 U
ratio of nanoparticles to enzymes while working with limited
amounts of lysosomes, but also ensuring suﬃcient amounts of
silk to permit zeta potential measurements as well as detection
and visualization by SEM) precluded the extension of these
degradation studies beyond the 5-day time point. However, the
lysosome-like model enzyme, papain,22 also showed an initially
slow silk nanoparticle degradation similar to that seen with the
isolated enzymes; therefore, we speculate that silk nanoparticles
would be fully degraded in lysosomes given longer exposure
cycles.
■ CONCLUSIONS
The presence of surface PEGylation hindered enzyme
accessibility and slowed silk degradation. Overall, silk nano-
particles showed a diﬀerential degradation behavior in response
to proteolytic enzymes, including lysosome-like enzymes (rank
order: protease XIV > papain ≫ α-chymotrypsin). Preliminary
studies with isolated lysosomal enzymes support the notion
that silk nanoparticles will be degraded within lysosomes. In
summary, this study provides the ﬁrst insight into the
proteolytic susceptibility of silk nanoparticles within target
cells, for example, cancer cells.
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